Naltrexone Maintenance Treatment of Alcoholism
Launched by THE SCRIPPS RESEARCH INSTITUTE · Nov 2, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets criteria for alcohol dependence.
- • Expresses a desire to cut down or stop drinking.
- Exclusion Criteria:
- • Currently meets criteria for dependence on substances other than alcohol.
- • History of opiate dependence or evidence of current opiate use.
- • Significant medical disorders that will increase potential risk or interfere with study participation.
- • Liver function tests more than 3 times normal or elevated bilirubin.
- • Female patients who are pregnant, nursing, or not using a reliable method of birth control.
- • Inability to understand and provide a consent form.
- • Treatment with an investigational drug during the previous month.
- • Prior treatment with naltrexone.
- • Chronic treatment with any narcotic-containing medications during the previous month.
- • Sensitivity to naltrexone as evidenced by adverse drug experiences especially with narcotic containing analgesics or opioid antagonists.
- • Current treatment with disulfiram.
- • More than 6 weeks of abstinence.
- • Meets criteria for a major psychiatric disorder and is in need of, or currently undergoing pharmacotherapy.
About The Scripps Research Institute
The Scripps Research Institute is a renowned non-profit biomedical research organization dedicated to advancing scientific knowledge and innovation in the life sciences. With a mission to enhance human health through groundbreaking research, Scripps Research conducts pioneering studies across various fields, including drug discovery, molecular biology, and immunology. The institute fosters a collaborative environment that integrates interdisciplinary approaches and state-of-the-art technologies, aiming to translate scientific discoveries into novel therapeutic interventions. Committed to excellence in research and education, Scripps Research plays a pivotal role in shaping the future of medicine and improving patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Patients applied
Trial Officials
Barbara Mason, Ph.D.
Principal Investigator
The Scripps Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials